Copyright
©The Author(s) 2005.
World J Gastroenterol. Jul 28, 2005; 11(28): 4344-4350
Published online Jul 28, 2005. doi: 10.3748/wjg.v11.i28.4344
Published online Jul 28, 2005. doi: 10.3748/wjg.v11.i28.4344
Table 2 Comparison between patients with and without phenotypic resistance in univariate analysis
| Patients with phenotypic resistance n = 18 | Patients without phenotypic resistance n = 17 | P | |
| Median (range) age (yr) | 34 (21-60) | 37(20-68) | 0.95 |
| Male (%) | 17 (94) | 13 (76) | 0.16 |
| Chinese (%) | 17/18 (94) | 17/17 (100) | 0.28 |
| Genotype (B:C:others) | 7B/ 7C/ 2 others | 11B /6C/ 2 others | 0.56 |
| Type of mutation (rtM204I:rtM204V:others) | 12:2:4 | 4:10:3 | 0.074 |
| Median (range) baseline ALT level, U/L | 96 (42-1 124) | 40 (16-143) | 0.018 |
| ALT level at emergence of genotypic resistance, U/L | 48 (22-82) | 36 (24-68) | 0.36 |
| Successful HBeAg seroconversion (%) | 12 | 17.7 | 0.43 |
| Median (range) baseline HBV DNA, Meq/mL | 249 (20-788) | 336 (20-1 680) | 0.17 |
| Median (range) peak HBV DNA after emergence of resistance, pg/mL | 186 (8.8-1 064) | 314 (9-3 920) | 0.33 |
| Median (range) duration of lamivudine at onset of resistance, wk | 88 (35-212) | 124 (36-202) | 0.16 |
| Median (range) duration of follow up after resistance, wk | 124 (52-204) | 102 (26-220) | 0.29 |
| Median (range) baseline CPT Score for cirrhotic patients, n = 10 | (n = 6) 8 (5-13) | (n = 4) 7 (5-9) | 0.038 |
- Citation: Dan YY, Wai CT, Lee YM, Sutedja DS, Seet BL, Lim SG. Outcome of lamivudine-resistant hepatitis B virus is generally benign except in cirrhotics. World J Gastroenterol 2005; 11(28): 4344-4350
- URL: https://www.wjgnet.com/1007-9327/full/v11/i28/4344.htm
- DOI: https://dx.doi.org/10.3748/wjg.v11.i28.4344